Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Six Week Radiographic Comparison of HipGrid® Drone™ and PhantomMSK® Hip

OrthoGrid announces a new clinical whitepaper for review. A retrospective evaluation was conducted for a consecutive cohort of patients having undergone unilateral total hip arthroplasty via the direct anterior approach between January 2017 and January 2020. All procedures were performed at a single site, by a single, fellowship trained orthopedic surgeon. Intraoperative fluoroscopy was supplemented…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Six Week Radiographic Comparison of HipGrid® Drone™ and PhantomMSK® Hip

OrthoGrid announces a new clinical whitepaper for review.

A retrospective evaluation was conducted for a consecutive cohort of patients having undergone unilateral total hip arthroplasty via the direct anterior approach between January 2017 and January 2020. All procedures were performed at a single site, by a single, fellowship trained orthopedic surgeon. Intraoperative fluoroscopy was supplemented by either the HipGrid®Drone™ (Drone) or PhantomMSK® Hip (Phantom) (OrthoGrid Systems Inc.

, Salt Lake City, UT, USA) to assist in the positioning of total hip arthroplasty components including cementless, short femoral stem and acetabular cup. The pre-defined target leg length discrepancy (LLD) and global hip offset (GHO) was less than 10mm and acetabular cup abduction angle (ABD) target was 45 degrees plus or minus 10 degrees for the Drone and 42 degrees plus or minus 10 degrees for the Phantom. Accuracy of component placement was evaluated on the six-week post-operative, weight bearing radiographs.

Fluoroscopy times were recorded directly from the c-arm imaging device and surgical times were defined as incision to wound closure. Percentages of patients achieving each component placement goal, as well as reaching all three accuracy goals, were also evaluated. Continuous variables were non-parametric, therefore, group differences were determined by the Mann-Whitney U test and categorical data were evaluated with the Fisher Exact test.

Click here to download the whitepaper:

Some of the data in this whitepaper were previously published in the Journal of Arthroplasty (DOI: 10/1016/j.arth.2020.06.053) by senior surgeon Dr. Cass Nakasone of Straub Medical Center, Bone and Joint Center, Honolulu, HI 96813. Click here to view the article on arthroplastyjournal.org.

To request a HipGrid Drone product demo or a PhantomMSK Hip software demo, please click here.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512